Skip to main content

Anson Funds Management LP

Position in SLNO — Soleno Therapeutics Inc

CIK 1491072 DALLAS, TX

Position in SLNO

as of Mar 31, 2026 · filed May 19, 2026
Position Value
$1,480,853
+$1,480,853 QoQ
Shares Held
44,231
Ownership
0.085%
of shares outstanding
% of Portfolio
0.26%
of 13F equity value
Holder Rank
#106
of 224 holders
Holding Since
Sep 2025
2 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Derivatives in SLNO

reported options exposure · as of Sep 30, 2025
CallValue
$8,788,000
CallShares
130,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Anson Funds Management LP holds $3,211,607 across 3 Biotechnology names. SLNO ranks #1 (46.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 SLNO
Soleno Therapeutics Inc
This page
44,231 $1,480,853

All Filings in SLNO

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,480,853 44,231
2025-09-30 $8,788,000 130,000